| 2025-12-01 |
详情>>
内部人交易：
Fluet Gregory等共交易7笔
|
| 2025-11-12 |
详情>>
股本变动：
变动后总股本834.05万股
|
| 2025-11-12 |
详情>>
业绩披露：
2026年一季报每股收益0.26美元,归母净利润213.60万美元,同比去年增长44.91%
|
| 2025-11-12 |
财报披露：
美东时间 2025-11-12 盘后发布财报
|
| 2025-09-30 |
股东大会：
将于2025-11-14召开股东大会
会议内容 ▼▲
- 1.Election of the eight directors named in the accompanying proxy statement, thereby setting the number of directors at eight;
2.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2026;
3.Approval, on a non-binding and advisory basis, of our executive compensation set forth in the accompanying proxy statement;
4.To recommend, on a non-binding advisory basis, whether executive compensation votes should occur every year, every two years or every three years;
|
| 2025-08-26 |
详情>>
业绩披露：
2025年年报每股收益0.89美元,归母净利润753.70万美元,同比去年增长46.35%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.63美元,归母净利润533.30万美元,同比去年增长60.54%
|
| 2025-02-11 |
详情>>
业绩披露：
2025年中报每股收益0.41美元,归母净利润344.20万美元,同比去年增长88.19%
|
| 2024-11-12 |
详情>>
业绩披露：
2025年一季报每股收益0.17美元,归母净利润147.40万美元,同比去年增长850.97%
|
| 2024-10-01 |
股东大会：
将于2024-11-15召开股东大会
会议内容 ▼▲
- 1.Election of the directors named in the accompanying proxy statement, thereby setting the number of directors at eight;
2.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2025;
3.Approval, on a non-binding and advisory basis, of our executive compensation set forth in the accompanying proxy statement;
|
| 2024-08-27 |
详情>>
业绩披露：
2024年年报每股收益0.60美元,归母净利润515.00万美元,同比去年增长62.67%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.39美元,归母净利润332.20万美元,同比去年增长55.74%
|
| 2024-02-13 |
详情>>
业绩披露：
2024年中报每股收益0.21美元,归母净利润182.90万美元,同比去年增长72.87%
|
| 2023-11-07 |
详情>>
业绩披露：
2024年一季报每股收益0.02美元,归母净利润15.50万美元,同比去年增长91.36%
|
| 2023-09-26 |
股东大会：
将于2023-11-10召开股东大会
会议内容 ▼▲
- 1.Election of the directors named in the accompanying proxy statement, thereby setting the number of directors at eight;
2.Approval of the Electromed, Inc. 2023 Equity Incentive Plan;
3.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2024;
4.Approval, on a non-binding and advisory basis, of our executive compensation set forth in the accompanying proxy statement;
|
| 2023-08-22 |
详情>>
业绩披露：
2023年年报每股收益0.37美元,归母净利润316.60万美元,同比去年增长37.35%
|
| 2022-09-27 |
股东大会：
将于2022-11-11召开股东大会
会议内容 ▼▲
- 1.Election of the directors named in the accompanying proxy statement, thereby setting the number of directors at eight;
2.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2023;
3.Approval, on a non-binding and advisory basis, of our executive compensation set forth in the accompanying proxy statement;
4.Transaction of any other business properly brought before the meeting or any adjournment thereof.
|
| 2021-09-30 |
股东大会：
将于2021-11-12召开股东大会
会议内容 ▼▲
- 1.Election of the directors named in the accompanying proxy statement, thereby setting the number of directors at seven;
2.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2022;
3.Approval, on a non-binding and advisory basis, of our executive compensation set forth in the accompanying proxy statement;
4.Transaction of any other business properly brought before the meeting or any adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-09-29 |
股东大会：
将于2020-11-13召开股东大会
会议内容 ▼▲
- 1.Election of the directors named in the accompanying proxy statement, thereby setting the number of directors at seven;
2.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2021;
3.Approval, on a non-binding and advisory basis, of our executive compensation set forth in the accompanying proxy statement;
4.Transaction of any other business properly brought before the meeting or any adjournment thereof.
|
| 2019-09-27 |
股东大会：
将于2019-11-15召开股东大会
会议内容 ▼▲
- 1.Election of the directors named in the accompanying proxy statement, thereby setting the number of directors at seven;
2.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm;
3.Approval, on a non-binding and advisory basis, of our executive compensation;
4.To recommend, on a non-binding advisory basis, whether executive compensation votes should occur every year, every two years or every three years;
5.Transaction of any other business properly brought before the meeting or any adjournment thereof.
|
| 2018-09-28 |
股东大会：
将于2018-11-16召开股东大会
会议内容 ▼▲
- 1.Election of the directors named in the accompanying proxy statement, thereby setting the number of directors at six;
2.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm;
3.Approval, on a non-binding and advisory basis, of our executive compensation;
4.Transaction of any other business properly brought before the meeting or any adjournment thereof.
|
| 2017-09-26 |
股东大会：
将于2017-11-10召开股东大会
会议内容 ▼▲
- 1.Election of the directors named in the accompanying proxy statement, thereby setting the number of directors at six;
2.Approval of the Electromed, Inc. 2017 Omnibus Incentive Plan;
3.Ratification of the appointment of RSM US LLP as our independent registered public accounting firm;
4.Approval, on a non-binding and advisory basis, of our executive compensation;
5.Transaction of any other business properly brought before the meeting or any adjournment thereof.
|
| 2016-10-03 |
股东大会：
将于2016-11-11召开股东大会
会议内容 ▼▲
- 1. Election of the directors named in the accompanying proxy statement, thereby setting the number of directors at six;
2. Ratification of the appointment of RSM US LLP as our independent registered public accounting firm;
3. Approval, on a non-binding and advisory basis, of our executive compensation;
4. Transaction of any other business properly brought before the meeting or any adjournment thereof.
|